MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.

<h4>Background</h4>In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways.<h4>Design and methods</h4>We analyzed eight miR-SN...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alfons Navarro, Carmen Muñoz, Anna Gaya, Marina Díaz-Beyá, Bernat Gel, Rut Tejero, Tania Díaz, Antonio Martinez, Mariano Monzó
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a74ca904399d4e798d20c7d4df13c8cf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a74ca904399d4e798d20c7d4df13c8cf
record_format	dspace
spelling	oai:doaj.org-article:a74ca904399d4e798d20c7d4df13c8cf2021-11-18T07:45:01ZMiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.1932-620310.1371/journal.pone.0064716https://doaj.org/article/a74ca904399d4e798d20c7d4df13c8cf2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23705004/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways.<h4>Design and methods</h4>We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS).<h4>Results</h4>The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P = 0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P = 0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P = 0.036). XPO5 (P = 0.039) and TRBP (rs784567) (P = 0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P = 0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039-6.620; P = 0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P = 0.008) and OS (P = 0.008).<h4>Conclusion</h4>miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse.Alfons NavarroCarmen MuñozAnna GayaMarina Díaz-BeyáBernat GelRut TejeroTania DíazAntonio MartinezMariano MonzóPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e64716 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alfons Navarro Carmen Muñoz Anna Gaya Marina Díaz-Beyá Bernat Gel Rut Tejero Tania Díaz Antonio Martinez Mariano Monzó MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.
description	<h4>Background</h4>In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways.<h4>Design and methods</h4>We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS).<h4>Results</h4>The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P = 0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P = 0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P = 0.036). XPO5 (P = 0.039) and TRBP (rs784567) (P = 0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P = 0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039-6.620; P = 0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P = 0.008) and OS (P = 0.008).<h4>Conclusion</h4>miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse.
format	article
author	Alfons Navarro Carmen Muñoz Anna Gaya Marina Díaz-Beyá Bernat Gel Rut Tejero Tania Díaz Antonio Martinez Mariano Monzó
author_facet	Alfons Navarro Carmen Muñoz Anna Gaya Marina Díaz-Beyá Bernat Gel Rut Tejero Tania Díaz Antonio Martinez Mariano Monzó
author_sort	Alfons Navarro
title	MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.
title_short	MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.
title_full	MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.
title_fullStr	MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.
title_full_unstemmed	MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.
title_sort	mir-snps as markers of toxicity and clinical outcome in hodgkin lymphoma patients.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/a74ca904399d4e798d20c7d4df13c8cf
work_keys_str_mv	AT alfonsnavarro mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT carmenmunoz mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT annagaya mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT marinadiazbeya mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT bernatgel mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT ruttejero mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT taniadiaz mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT antoniomartinez mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients AT marianomonzo mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
_version_	1718423054089977856

MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients.

Ejemplares similares